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Summary Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and
60 mCi of a I3'1 radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour.
Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow
suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or
clinical response. Six of these demonstrated an event-free response that was maintained for periods of between
7 and 26 months.
While murine monoclonal antibodies have made a major
contribution to the field of diagnostic histopathology, their
place as therapeutic reagents remains speculative. Many are
capable of initiating human immune mechanisms and are
interesting as potential biological response modifiers (Miller
et al., 1983; Cheung et al., 1978). Others are potentially
useful in a wide variety of malignancies as passive delivery
systems for drugs (Embleton et al., 1983; Kulkarni et al.,
1981), toxins (Jansen et al., 1982; Thorpe et al., 1985) and
radio-isotopes (Larson et al., 1983; Carasquillo et al., 1984).
Unfortunately, intravenous administration of '"'I radio-
labelled antibodies to patients has met with limited success.
This probably reflects the low levels of isotope accumulation
in solid tumour deposits. Several tumour resection studies
have demonstrated that only approximately 0.001% of
injected dose binds to each gram of tumour (Esteban et al.,
1987; Burraggi et al., 1985). These levels are too low to
deliver effective radiotherapy before marrow toxicity occurs
(Humm, 1986; Vaughan et al., 1987).
These observations led us and others (Lashford et al.,
1988; Epenetos et al., 1987) to investigate the role of radiola-
belled monoclonal antibodies in the treatment of intracavity
extensions of tumour. The intrathecal compartment appears
particularly amenable to this approach for three reasons.
Firstly, neoplastic meningitis is essentially a leptomeningeal
disease (Azzarelli, 1977; Olson et al., 1974). Secondly, the
CSF provides a natural circulatory mechanism for the dist-
ribution of antibodies. Finally, there is a clinical need to
improve the therapy of this condition (Chessells, 1985;
Cumberlin et al., 1979; Hitchins et al., 1987).
This paper reports the results of a pilot study of '"'I
radiolabelled monoclonal antibodies in the treatment of lep-
tomeningeal tumours.
Materials and methods
Patient selection
Patients included in the study had failed an adequate trial of
conventional therapy and had evidence of leptomeningeal
dissemination of tumour.
The immunophenotype of each patient's tumour was ascer-
tained by screening either frozen tumour biopsies or air dried
cytospins with a panel of monoclonal antibodies (either
indirect immunofluorescence or indirect peroxidase).
Antibodies were selected for radiation targeting based on
their immunoreactivity with the patients tumour and lack of
binding to normal central nervous system (CNS) com-
ponents.
Each patient underwent a clinical assessment which
included serum and cerebrospinal fluid (CSF) biochemistry,
CSF cell count and morphology, full blood count, cranial CT
scanning with contrast and myelography. Patients were not
excluded from treatment on the basis of their clinical condi-
tion, but were excluded if they had evidence of a solid
parenchymal metastasis. In the majority of cases, those with
evidence of a spinal block were referred for limited
radiotherapy to the affected spinal segments.
Preparation ofthe radiolabelled conjugate
Antibodies were radiolabelled by either the Chloramine-T or
the Iodogen method to a specific activity of between 5 and
15 mCi mg-' of protein. Free iodine was separated from the
radiolabelled protein by Sephadex G25 column chromato-
graphy. Antibody was passed through a 0.22ym filter and
collected into a sterile evacuated vial.
To determine the degree of microaggregates and free
iodine in the radiolabelled protein preparations, they were
subjected to Sephacyl S300 column chromatography and
precipitation with 10% trichloroaceric acid. In the first five
administrations, immunological activity was assessed by an
indirect immunofluoresence assay (Allan et al., 1983). Due to
the insensitivity of this technique, later preparations were
assayed for the proportion of immunoreactive radiolabelled
antibody in a direct radioimmunoassay under conditions of
antigen excess (Zalutsky et al., 1989). Due to logistical
reasons, it was not always possible to test for immunoreac-
tivity directly after radiolabelling, hence the administration of
material with low antigen binding in two individuals.
Patient preparation and administration ofconjugate
Thyroid blockade was performed either with 0.3 ml Lugol's
iodine t.d.s. and Liothyronine 8 Ag b.d. or by Liothyronine
80 lAg daily supplemented with 10 drops of supersaturated
potassium iodide q.d.s. and 200 mg of potassium perchlorate
q.d.s. In anticipation of a meningitic reaction associated with
the introduction of protein into the CSF, all patients were
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placed on low dose dexamethasone, 1 mg t.d.s. This was
tailed off over a period of 3 weeks following therapy.
Radiolabelled protein was administered via a 0.22 ytm
Millex filter by direct lumbar administration (3/15 patients),
via an intraventricular Ommaya Reservoir (10/15 patients) or
by both routes (2/15 patients). On each occasion, a sample of
CSF was withdrawn equivalent in volume to the solution of
radiolabelled antibody. Cannulae and reservoirs were flushed
with approximately 2 ml of sterile 0.9% saline.
Immunoscintigraphy
Scintigrams of the total neuraxis were obtained as soon as
the patients' clinical condition allowed. Initial scintigrams
were obtained 5-7 days after therapy when whole body
radioactivity had diminished to a level of 20 mCi. These were
reported by a radiologist who was unaware of the other
clinical and radiological findings.
Response to therapy
Patients were evaluable for response if they had not received
either chemotherapy for 4 weeks before antibody treatment
or radiotherapy to all evaluable sites within the preceding 6
weeks. These conditions were waived if the patients had clear
evidence of disease progression in the intervening period.
Response was assessed at 3 + months by clinical criteria
and by imaging and cytological evidence of tumour reduc-
tion.
Results
Fifteen patients with a heterogeneous group of tumours were
enrolled into the study. Of these, five presented with
primitive neuroectodermal tumours (four medulloblastoma
and one pineoblastoma), two with gliomas, two with
melanoma metastasising to the CNS, one with a B-cell lym-
phoma, one with a spinal teratoma and four with car-
cinomatous meningitis. A briefclinical history ofeach patient
and details of the radiolabelled antibody each received are
given in Table I.
Antibody preparation
Antibody preparations were relatively free from microag-
gregates (mean value 1%, range 0.5%; n = 13), and free
iodine (mean value 4.1%; range 1-13%; n = 14). In the first
five patients, the antibody always retained biological activity
as determined by the indirect immunofluoresence assay. In
two of the remaining 10 radiolabellings, the immunoreac-
tivity of the protein was substantially reduced (patients 6 and
12, less than 2% immunoreactive fraction).
Sites of isotope accumulation
The biodistribution of radionuclide, as demonstrated by
scintigraphy, varied with both the pattern of tumour distribu-
tion and the antibody used. Some accumulation of "'1I in the
liver and spleen was noted on all occasions. This was most
Table I Synopsis of patients treated by intrathecal targeted radiation therapy
Pt MIA
no. Disease Prior treatment therapy
1 Pineoblastoma Surgery 24 mCi
Cranial radiation (4,880 cGy). UJ181.4(4)
2 B-cell Surgery
Lymphoma Neuraxis radiation (3,000cGy). 40mCi
Radiation to tumour sites (4,500 cGy). F8.11.13(12)
VAC, I/T Mtx.
3 Spinal teratoma Surgery.
Neuraxis radiation (3,500 cGy). 11 mCi
Radiation to tumour site (5,500 cGy). UJ181.4
VP16, iphosphamide, carboplatin.
4 Medulloblastoma Surgery. 40 mCi
Cranial radiation (5,550 cGy). UJl81.4
Radiation to T8-L1 (1,500 cGy).
5 Melanoma Surgery 45 mCi
Mel-14(')
6 Medulloblastoma Surgery. 35 mCi
Neuraxis radiation, total tumour dose, 10,500 cGy. UJ181.4
VCR, CCNU.
7 Medulloblastoma Surgery. 46.5 mCi
Neuraxis radiation, tumour dose, 6,000 cGy. UJI81.4
8 Melanoma Surgery. 60 mCi
Cranial radiation, tumour dose, 7,300 cGy. Mel-14
9 Ovarian Neuraxis radiation (3,000 cGy). 55mCi
carcinoma I/T Mtx. HMFGI(28)
10 Bladder No prior CNS therapy. 58 mCi
carcinoma HMFGI
11 Gliomatosis Surgery. 60 mCi
Radiation to tumour site (4,500 cGy). 81C6(3)
12 Medulloblastoma Surgery.
Neuraxis radiation, tumour dose 6,000 cGy.
Post fossa radiation (5,550 cGy). 48 mCi
MOPP UJI81.4
I/T cytosine, Mtx., hydrocortisone.
Carboplatin, cyclo, Mtx., VCR.
13 Gliomatosis Surgery. 60 mCi
Radiotherapy. 81.C6
Chemotherapy.
14 Breast carcinoma Surgery. 56 mCi
Cervical lymph node radiation. HMFGI
Post fossa radiation.
15 Lung carcinoma I/T Mtx. 58 mCi
HMFGI
VAC, vincristine + actinomycin D + cyclophosphamide. IT MTX, intrathecal methotrexate. VCR,
vincristine. MOPP, mustine + vincristine + prednisolone + procarbazine. Cyclo,cylcophosphamide. M/A,
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marked in individuals receiving antibodies Mel-14 and 81C.6.
Patients who received radiolabelled Mel-14 were also noted
to have pronounced skeletal accumulation of radionuclide.
The distribution of radionuclide within the neuraxis cor-
related well with the anticipated distribution of tumour
(Table II). Seven unexpected areas of isotope accumulation
were noted. These were not consistent between patients and
comprised of: posterior fossa uptake in two patients (patients
4 and 12), and four additional spinal sites observed in
patients 1, 11, 14 and 15. An abdominal foci in patient 9
with malignant meningitis secondary to ovarian carcinoma
was noted. This patient was suspected as having residual
abdominal disease as determined by CT scan, but the
evidence was not conclusive.
Toxicity
Aseptic meningitis The major toxicity noted was the occur-
rence of an acute aseptic meningitis. This occurred in 7/15
patients and was characterised by a triad ofheadache, nuchal
rigidity and nausea and vomiting. Symptoms typically began
at 4-6 h after administration of the conjugate and persisted
for 8-12 h. In two patients, symptoms were protracted, per-
sisting for 48 h (patients 9 and 12). The meningitic reaction
was associated with a pyrexia of between 37.5 and 38.5°C on
three occasions. CSF examination in these patients demon-
strated a sterile leucocytosis.
Bone marrow suppression Out of the 15 patients in the
study, only eight were evaluable for bone marrow toxicity.
Of the seven excluded, one died within 72 h and three within
6 weeks of therapy. One patient was lost to follow-up due to
leaving the country, one rapidly lost their radiolabelled
antibody from the CSF due to the clip closing off the shunt
slipping and one received chemotherapy within 4 weeks of
targeted radiation therapy. Three of the remaining eight
patients developed reversible bone marrow suppression after
receiving 55-60 mCi ofeither HMFG1 (patients 9 and 14) or
Mel-14 (patient 8) (Table I). The nadir in peripheral blood
counts occurred at week 5 in patient 8 (Hb 7.6 gdl-'; WCC
0.8 x 1091-; platelets 23 x 103 1-). The nadir in counts for
patient 9 also occurred at week 5 (Hb 5.7 g dl-';
WCC 3.1 x 109 1'- ; platelets 89 x IO3 1-). In patient 14, the
nadir in peripheral blood count occurred at week 4
(Hb 7.4 g dl-'; WCC 2.1 x 1091-l; platelets: 76 x I03 1'). A
return to a normal peripheral blood count was noted in all
patients by week 9.
Neurological disturbance Two forms of neurological distur-
bance were observed in the study. Transient parasthesiae
over sacral dermatomes was reported by patient 4. This
symptom resolved within a few minutes of completing the
injection. More concerning was the development of seizures
in patients 10 and 14. Patient 10 presented with a history of
progressive dementia and two grand mal seizures. In the
week before therapy, the patient had signs of raised intra-
cranial pressure and was deteriorating clinically. Injection of
58 mCi of radiolabelled HMFG1 produced a mild headache
that lasted for 4-6 h. Forty-eight hours after administration
of the conjugate, the patient was found drowsy and unre-
sponsive. This state reversed in 20 min and was attributed to
an unwitnessed seizure. The patient died suddenly 24 h later,
possibly as a result of a further unwitnessed seizure.
Post-mortem revealed extensive involvement ofthe cerebral
leptomeninges by tumour. In addition, marked acute
oedematous and reactive changes were noted in the ven-
tricular and subpial white matter. Milder oedematous
changes were noted in white matter away from the CSF
surfaces.
The second patient also received 60 mCi of `3'I HMFG1,
Table II Localisation of radiolabelled monoclonal antibodies following intrathcal administration
Patient Tumour extent
1 CSF cell count 153 x 1O6 Il
Infiltration left optic nerve.
Multiple spinal deposits.
2 CSF cell count 372 x 106 Il
III, IV and VI cranial nerve palsies.
VII LMN cranial nerve palsy.
3 Tumour cells on cytospin.
Spinal block L3-4.
4 Multipe spinal deposits.
5 Infiltration cortical pia.
Tumour residue left, cerebral cortex.
Quadrigeminal plate.
Multiple deposits T12-L2.
6 Tumour cells on cytospin.
Cystic mass posterior fossa.
7 Posterior fossa.
Diffuse thoracic cord encasement.
8 Tumour cells on cytospin.
Non-enhancing lesion right occiput.
9 Tumour cells on cytospin.
Left VI cranial nerve palsy.
Lumbar-sacral nerve roots.
10 CSF cell count > 1,000 x 106 1-1
11 Tumour cells on cytospin.
Intraventricular extension of tumour.
12 No evaluable disease.
13 Tumour cells on cytospin.
14 Tumour cells on cytospin.
Multiple cranial nerve palsies.
Sacral nerve routes.
15 Tumour cells on cytospin.
Multiple deposits sacral recess thecal sac.
Radio-immunoscintigraphy
Left optic nerve.
Marked, irregular accumulation of isotope
in lumbar expansion.
Persistent focus right side of face.
No focal accumulation.
Lumbar, sacral and mid-thoracic spine.
Posterior fossa.
Left cerebral cortex.
Lumbar spine.
Posterior fossa, right > left.
Left cerebral cortex.
Posterior fossa.
Thoracic spine.
Occipital pole right hemisphere.
Superior surface cerebral cortex.
Sacral spine.
Abdominal focii.
Not scanned.
Ventricular persistence.
Basal cisterns.
Thoracic spine.
Sacral spine.
Posterior fossa.
Ventricular persistence.
Intra-abdominal.
Single scintigram 21 days.
3 foci head.
Lumbar spine.
Diffuse cortical uptake.
Single focus lumber spine.
LMN, lower motor neurone.640 R.P. MOSELEY et al.
but had no previous history of seizures (patient 14). Follow-
ing a progressive improvement in her clinical state, she sud-
denly developed status epilepticus 10 days after antibody
administration. The patient required treatment with a con-
tinuous chlormethiazole infusion before making a clinical
recovery. No clear precipitating cause was identified for her
sudden deterioration.
Response to therapy
Of the 15 patients enrolled in the study, nine were evaluable
for a tumour response (Tables III and IV). Patient 6 was
excluded as retrospective analysis revealed she had received
an essentially biologically inactive conjugate and patients 7
and 9 received conventional radiotherapy within 6 weeks
before the administration of the radiolabelled conjugate.
Patient 10 died within 72 h of targeted therapy, patient 12
had no evaluable disease at the time of therapy and in
patient 3 the clip shutting off a VP shunt slipped, resulting in
the loss of radiolabelled antibody from the CNS.
Of the nine evaluable patients, eight had significant clinical
signs at the time of treatment. Five demonstrated a marked
improvement in clinical condition, which continued for at
least 7 months from treatment (Table IV). The improvement
in neurological status was accompanied by an objective
tumour response in these and in a sixth asymptomatic
patient.
Table IV Survival of evaluable patients after receiving targeted
radiotherapy
Patient Event-free survival Overallpatient survival
(months) (months)
1 10' 24
2 12 12
3 PDb 1
4 7 48c
5 8 12
8 9 32d
10 Toxic death 0.1
11 PD 1
14 26 26C
15 PD 4
'After this time the patient begain a slow progressive clinical
deterioration. bPD,progressivedisease.cRemainsaliveanddisease-free.
dAlive with disease.
The event-free survival of the responding group ofpatients
is given in Table IV. This ranged from 7 to 26 months (mean
12; median 9.5 months). Patient 1 showed a marked
deterioration 10 months from therapy and gradually declined
over the next 14 months. Patient 2 died of systemic disease at
12 months. Patient 4 suffered a focal spinal relapse at 7
months which was treated by localised external beam
radiotherapy. She remains alive and well 48 months after
Table III Response of patients to targeted radiation therapy
Clinical Clinical
Patient status Clinical signs response Measurable response
I Recurrent Confused.
disease Cachectic.
Nuchal rigidity.
Optic atrophy.
Paraparesis.
2 Progressive Confused.
disease on Rx. Nuchal rigidity.
Multipe UMN cranial nerve
palsies.
LMN VII palsy.
3 Progressive
disease on Rx.
4 Recurrent
disease
5 Residual disease
6 Recurrent
disease
7 Recurrent
disease
8 Recurrent
disease
9 Progressive
disease on Rx.
10 New disease
I I Recurrent
disease
12 Recurrent
disease
13 Recurrent
disease
14 New disease
15 Recurrent
disease
CR CR-CSF varameters.
CR
CR
NR
I
CR
CR
CR
I
NR
CR
CR
NR
I
Paraparesis.
Paraparesis.
Raised ICP.
Epilepsy.
Ataxia.
Raised ICP.
Ataxia.
Ataxia.
Paraparesis.
Sensory level T6.
Asymptomatic
Paraparesis.
Incontinent.
VI Cranial nerve palsy.
Dementia.
Raised ICP.
Grand mal fits.
Raised ICP.
Paralysis, downward gaze.
L homonymous hemianopia.
NED
Raised ICP.
L Ptosis.
Multiple cranial nerve palsies.
Ataxia.
Decreased sensation.
Paraparesis.
Decreased sacral sensation.
VII Cranial nerve palsy
CR
CR
I
NR
NR
NR
NR
NR
I
CR
NR
NR
Repeat myelography
performed.
CR-CSF parameters.
NR.
CR-myelography.
CR-CAT imaged lesion
head. Repeat myelography
performed.
Not assessed
Not assessed
CR on CSF parameters
CR on CSF parameters
Repeat myelography
performed.
Toxic death
Progressive disease.
Not assessed
Progressive disease.
CR-CSF parameters.
Progressive disease.
ICP, intra-cranial pressure. UMN/LMN, upper/lower motor neurone. NED, no evaluable disease.
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treatment. Patient 8 developed solitary recurrences at 9 and
30 months and remains alive with disease 32 months from
targeted therapy. Patient 14 remains alive and disease-free 26
months after treatment. The mean overall survival of the
evaluable patients is 16 months with a median of 12 months.
Discussion
The central nervous system is a recognised site for secondary
deposits of tumour. Tumour metastases may present as either
solid parenchymal deposits or as a neoplastic meningitis. The
frequency ofthe latter manifestation varies with tumour type,
but is reported to occur in 4-5% of patients with non-
Hodgkin's lymphoma and in a substantial proportion of
carcinomas.
This pilot study of '3'I monoclonal antibody has illustrated
the potential for targeting such tumour sites. Five to seven
days after treatment, scintigraphy demonstrated many areas
of radionuclide accumulation which invariably correlated
with the clinical and radiological pattern of the disease
(Table II). Despite this strong qualitative association between
radioimmunolocalisation and clinical disease, we have not
reported sensitivity of immunoscintigraphy as myelographic
findings were frequently reported as 'multiple spinal deposits'
and the imaging characteristics of the 13'I make it difficult to
separate out small foci of disease in close proximity.
Of course, concordance between disease sites and radioim-
munolocalisation cannot be taken as direct evidence of selec-
tive targeting. Non-specific localisation is possible due to
both disturbed vascular flow in tumours and non-specific
trapping within cysts (Primus et al., 1977; Goldenberg et al.,
1974). While is has been possible to demonstrate selective
uptake of specific antibody on malignant cells in the CSF in
one patient (patient 1) immunolocalisation was also noted in
two patients administered radiolabelled monoclonal antibody
with <2% immunoreactive fraction (patients 6 and 12)
(Table II). Consequently, we do not know if the accumula-
tion of radionuclide in these patients was due to non-specific
uptake of radionuclide or to the small fraction of
immunoreactive antibody present in the preparation.
The toxicity of the administered conjugate may be attri-
buted to both the antibody and the radionuclide. The high
incidence of aseptic meningitis is felt to be due to the intro-
duction of antibody into the CSF pathways as this complica-
tion has been reported with other intrathecally administered
proteins such as human serum albumin (DiChiro, 1973). The
incidence of aseptic meningitis complicating cisternography
was related to the preparation of 131I albumin and could be
reduced by changing the albumin source. Consequently, more
stringent quality control of intrathecally administered
antibodies may reduce the frequency of this complication.
Other toxicities appear to be related to the dose of
administered radionuclide. Three out of four evaluable
patients given 55-60mCi had evidence of bone marrow
suppression. Two ofthese patients probably had an enhanced
bone marrow dose due to the biological characteristics ofthe
monoclonal antibody. The first patient (patient 8) had
marked bony/bone marrow accumulation of '"'I Mel-14. The
underlying reason for uptake at this site is uncertain as
immunohistological studies do not,suggest that bone or bone
marrow express the Mel-14 antigen. The second patient
(patient 9) was noted to generate large molecular weight
complexes in serum. These wereikely to be immune com-
plexes, formed from either circulating antigen or a pre-
existing anti-mouse immunoglobulin (Courtenay-Luck et al.,
1986). The presence ofsuch complexes results in an enhanced
reticuloendothelial clearance of conjugate.
Serious neurotoxicity was noted in two patients who
received 55 and 56 mCi of "3'I HMFG1. Both developed
seizures, one died and came to post-mortem. It was impossi-
ble to be certain about the cause of death as his-
topathological examination of the brain demonstrated both
widespread tumour infiltration and oedema. The degree of
oedema was felt to be disproportionate to the tumour
infiltration and thus may have been particularly attributable
to an acute radiation effect. It is possible that a sudden rise
in intracranial pressure caused by this would be sufficient to
cause death in an already compromised patient.
The combination of marrow toxicity and neurotoxicity at
approximately 60mCi ofisotope suggests that phase I studies
should commence at lower doses. This is endorsed by the
encouraging number of responses to "3'I monoclonal
antibody at or below this dose. Of evaluable patients studied
67% demonstrated a major sustained clinical response which
was invariably associated with a return of CSF parameters to
normal. Details of pharmacokinetics and dosimetric studies
on these patients are discussed in two separate publications,
one dealing with the lumbar (Richardson et al., 1990)
administration of antibodies and the other the intraven-
tricular administration of conjugates.
The results from this study are sufficiently encouraging to
continue with a full phase I/II study for patients with medul-
loblastoma, carcinomatous meningitis and lymphopro-
liferative disease within the CNS. It may also prompt other
groups to investigate alternative targeted agents within a
closed compartment such as the CSF pathways.
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